In the News

The US Food and Drug Administration issued an emergency use authorisation (EUA) for baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalised adults and paediatric patients aged 2 years and older...

Obese people aged 50 years and younger are more likely to be hospitalised with coronavirus disease 2019 (COVID-19) and are at higher risk of in-hospital death or mechanical ventilation, according to a study published in Circulation.

For the study, Nicholas Hendren, MD, University...

An independent data and safety monitoring board (DSMB) overseeing the phase 3 trial of the investigational coronavirus disease 2019 (COVID-19) vaccine known as mRNA-1273 reviewed trial data and found that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults.

The...

Using a life support machine to replicate the functions of the heart and lungs significantly improved the survival of people who suffered from out-of-hospital cardiac arrest, according to a study published in The Lancet.

The treatment program involving extracorporeal membrane...

While patients with coronavirus disease 2019 (COVID-19) should be treated with standard anticoagulation therapies, a new study published in Thrombosis Research showed that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and...

By Denise Baez

Adult outpatients with symptomatic coronavirus disease 2019 (COVID-19) treated with fluvoxamine had a lower likelihood of clinical deterioration over 15 days compared with patients treated with placebo, according to a preliminary study published in JAMA.

...

By Denise Baez

NEW YORK -- November 13, 2020 -- Hospitalised patients with coronavirus disease 2019 (COVID-19) who received an inhaled, nebulised formulation of interferon beta-1a (SNG001) had greater odds of improvement and recovered more rapidly from severe acute respiratory syndrome...

By Denise Baez

Patients with multiple myeloma who were hospitalised with coronavirus disease 2019 (COVID-19) had a high mortality rate, with significant geographic variability, ranging from 27% to 57%, according to the first results from the International Multiple Myeloma COVID-19 dataset...

By Denise Baez

Early elevation of the Fibrosis-4 (FIB-4) index score is independently associated with adverse among patients hospitalised with coronavirus disease 2019 (COVID-19), according to a study published in Clinical Infectious Diseases.

The FIB-4 index was developed...

The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild and moderate coronavirus disease 2019 (COVID-19) in non-hospitalised adult and paediatric patients.

...

Pages